Genetic susceptibility of diabetic retinopathy

Current Diabetes Reports

Volumn 8, Issue 4, 2008, Pages 257-262

  Patel, Shrena ^b   Chen, Haoyu ^b   Tinkham, Nicholas H ^b   Zhang, Kang ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN; ANGIOPOIETIN 1; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN A;

ANEMIA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOXIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PREVALENCE; RACE DIFFERENCE; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; REVIEW; VISUAL IMPAIRMENT; ANIMAL; GENETICS; PATHOLOGY;

ANGIOPOIETIN-1; ANIMALS; DIABETIC RETINOPATHY; ERYTHROPOIETIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52649133999     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0046-6     Document Type: Review

References (50)

1. Varma R, Macias GL, Torres M, et al.: Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology 2007, 114:1332-1340.
2. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet 2001, 17:502-510.
3. Yang Z, Camp NJ, Sun H, et al.: A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006, 314:992-993.
4. Dewan A, Liu M, Hartman S, et al.: HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006, 314:989-992.
5. Klein RJ, Zeiss C, Chew EY, et al.: Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
6. Grant SF, Thorleifsson G, Reynisdottir I, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
7. International HapMap Consortium: A haplotype map of the human genome. Nature 2005, 437:1299-1320.
8. Pritchard JK: Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001, 69:124-137.
9. Garcia CK, Wilund K, Arca M, et al.: Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001, 292:1394-1398.
10. Harris MI, Klein R, Cowie CC, et al.: Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care 1998, 21:1230-1235.
11. Warpeha KM, Chakravarthy U: Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003, 17:305-311.
12. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
13. Saxena R, Voight BF, Lyssenko V, et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336.
14. Scott LJ, Mohlke KL, Bonnycastle LL, et al.: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
15. Sladek R, Rocheleau G, Rung J, et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
16. Zeggini E, Weedon MN, Lindgren CM, et al.: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.
17. Field LL: Genetic linkage and association studies of type I diabetes: challenges and rewards. Diabetologia 2002, 45:21-35.
18. Hanis CL, Hallman D: Genetics of diabetic retinopathy. Curr Diab Rep 2006, 6:155-161.
19. Aiello LP: Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005, 353:839-841.
20. Watanabe D, Suzuma K, Matsui S, et al.: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005, 353:782-792.
21. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothetial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487.
22. Enge M, Bjarnegard M, Gerhardt H, et al.: Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002, 21:4307-4316.
23. Ladomery MR, Harper SJ, Bates DO: Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007, 249:133-142.
24. Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865.
25. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L: Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant 2007, 22:827-832.
26. Suganthalakshmi B, Anand R, Kim R, et al.: Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006, 12:336-341.
27. Yang B, Cross DF, Ollerenshaw M, et al.: Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 2003, 17:1-6.
28. Awata T, Inoue K, Kurihara S, et al.: A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002, 51:1635-1639.
29. Lip PL, Chatterjee S, Caine GJ, et al.: Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 2004, 88:1543-1546.
30. Watanabe D, Suzuma K, Suzurna I, et al.: Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005, 139:476-481.
31. Clarke M, Dodson PM: PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab 2007, 21:573-586.
32. Chen J, Connor KM, Aderman CM, Smith LE: Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118:526-533.
33. Tong Z, Yang Z, Patel S, et al.: Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 2008, 106:6998-7004.
34. Fukumura D, Gohongi T, Kadambi A, et al.: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001, 98:2604-2609.
35. Chen Y, Huang H, Zhou J, et al.: Polymorphism of the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans. Mol Vis 2007, 13:2142-2147.
36. Abiko T, Abiko A, Clermont AC, et al.: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003, 52:829-837.
37. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003, 26:1589-1596.
38. Sozmen EY, Sozmen B, Delen Y, Onat T: Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res 2001, 32:283-287.
39. Hudson BI, Hofmann MA, Bucciarelli L, et al.: Glycation and diabetes: The RAGE connection. Curr Sci 2002, 83:1515-1521.
40. Ramprasad S, Radha V, Mathias RA, et al.: Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. Eye 2007, 21:395-401.
41. Gardiner TA, Anderson HR, Stitt AW: Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 2003, 201:328-333.
42. Barile GR, Pachydaki SI, Tari SR, et al.: The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005, 46:2916-2924.
43. Richeti F, Noronha RM, Waetge RT, et al.: Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis 2007, 13:740-745.
44. Demaine A, Cross D, Millward A: Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000, 41:4064-4068.
45. Kao YL, Donaghue K, Chan A, et al.: An aldose rcductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Pract 1999, 46:155-160.
46. Girach A, Vignati L: Diabetic microvascular complications - can the presence of one predict the development of another? J Diabetes Complications 2006, 20:228-237.
47. Klein R, Klein BE: Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care 1998, 21(Suppl 3):C39-C43.
48. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, et al.: Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 2001, 24:1-11.
49. Trevisan R, Vedovato M, Mazzon C, et al.: Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients. Diabetes Care 2002, 25:2026-2031.
50. Parving HH, Mauer M, Ritz E: Diabetic nephropathy. In The Kidney. Edited by Brenner BM. Philadelphia: Elsevier; 2004:1777-1818.